Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas
- PMID: 29671892
- PMCID: PMC6758559
- DOI: 10.1111/his.13525
Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas
Abstract
Aims: Dedifferentiated endometrial carcinomas (DDECs)/undifferentiated endometrial carcinomas (UECs) are aggressive endometrial cancers with frequent genomic inactivation of core components of switch/sucrose non-fermentable (SWI/SNF) complex proteins. Claudin-4, an epithelial intercellular tight junction protein, was recently found to be expressed in SWI/SNF-deficient undifferentiated carcinomas but not in SWI/SNF-deficient sarcomas. The aim of this study was to examine claudin-4 expression in UECs/DDECs and other high-grade uterine carcinomas.
Methods and results: We examined claudin-4 expression by immunohistochemistry (clone 3E2C1) on tissue microarrays that contained 44 UECs/DDECs (24 SWI/SNF-deficient), 50 carcinosarcomas, 164 grade 3 endometrioid carcinomas, 57 serous carcinomas, and 20 clear cell carcinomas. Tumours with <5% claudin-4 expression were considered to be negative. Nearly all SWI/SNF-deficient, and most SWI/SNF-proficient, UECs/DDECs showed a complete absence of claudin-4 expression in the undifferentiated component, whereas the differentiated component in DDECs showed consistent and diffuse claudin-4 expression. Only one SWI/SNF-deficient DDEC showed focal expression of claudin-4 in the undifferentiated component, as compared with diffuse expression in the corresponding differentiated component. Claudin-4 expression was consistently absent in the sarcomatous component of carcinosarcoma, and it was absent in 24% of grade 3 endometrioid carcinomas and serous carcinomas.
Conclusion: Claudin-4 expression can be absent or very focal in a subset of high-grade endometrial carcinomas, and is almost always absent in the undifferentiated components of SWI/SNF-deficient UECs/DDECs, despite the apparent epithelial origin in the case of DDECs. Therefore, claudin-4 expression cannot be used to infer mesenchymal or epithelial tumour origin in the endometrium. The consistent loss or down-regulation of claudin-4, a tight junction protein, in SWI/SNF-deficient UECs/DDECs further supports the undifferentiated nature of these tumours.
Keywords: SWI/SNF proteins; claudin-4; endometrial cancer; endometrioid adenocarcinoma; undifferentiated carcinoma; uterine sarcomas.
© 2018 John Wiley & Sons Ltd.
Conflict of interest statement
Figures
Similar articles
-
Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.Histopathology. 2016 Oct;69(4):560-9. doi: 10.1111/his.12989. Epub 2016 Jul 5. Histopathology. 2016. PMID: 27101785 Free PMC article.
-
Endometrial neuroendocrine carcinoma and undifferentiated carcinoma are distinct entities with overlap in neuroendocrine marker expression.Histopathology. 2022 Jul;81(1):44-54. doi: 10.1111/his.14639. Epub 2022 May 5. Histopathology. 2022. PMID: 35394077
-
Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.Am J Surg Pathol. 2018 Jan;42(1):76-83. doi: 10.1097/PAS.0000000000000941. Am J Surg Pathol. 2018. PMID: 28863077 Free PMC article.
-
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.Gynecol Oncol. 2021 May;161(2):629-635. doi: 10.1016/j.ygyno.2021.02.029. Epub 2021 Mar 10. Gynecol Oncol. 2021. PMID: 33712277 Review.
-
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491. Int J Gynecol Pathol. 2019. PMID: 30550483 Free PMC article. Review.
Cited by
-
Rapid progression of disease in two cases of undifferentiated endometrial carcinoma.Gynecol Oncol Rep. 2019 Jan 18;27:65-68. doi: 10.1016/j.gore.2019.01.004. eCollection 2019 Feb. Gynecol Oncol Rep. 2019. PMID: 30723762 Free PMC article.
-
Claudins in Cancer: A Current and Future Therapeutic Target.Int J Mol Sci. 2024 Apr 24;25(9):4634. doi: 10.3390/ijms25094634. Int J Mol Sci. 2024. PMID: 38731853 Free PMC article. Review.
-
Re-expression of SMARCA4/BRG1 in small cell carcinoma of ovary, hypercalcemic type (SCCOHT) promotes an epithelial-like gene signature through an AP-1-dependent mechanism.Elife. 2020 Dec 23;9:e59073. doi: 10.7554/eLife.59073. Elife. 2020. PMID: 33355532 Free PMC article.
-
Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.Virchows Arch. 2019 Jul;475(1):85-94. doi: 10.1007/s00428-019-02532-w. Epub 2019 Feb 9. Virchows Arch. 2019. PMID: 30739164
-
Claudins: New Players in Human Fertility and Reproductive System Cancers.Cancers (Basel). 2020 Mar 18;12(3):711. doi: 10.3390/cancers12030711. Cancers (Basel). 2020. PMID: 32197343 Free PMC article. Review.
References
-
- Coatham M, Li X, Karnezis AN et al. Concurrent arid1a and arid1b inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol 2016;29;1586–1593. - PubMed
-
- Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005;29;1316–1321. - PubMed
-
- Kuhn E, Ayhan A, Bahadirli-Talbott A, Zhao C, Shih Ie M. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol 2014;38;660–665. - PubMed
-
- Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartmann A, Haller F. Smarca4-deficient pulmonary adenocarcinoma: Clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent ttf1neg/ck7pos/heppar-1pos immunophenotype. Virchows Arch 2017;471;599–609. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
